Within hours of the news that the J.P. Morgan (JPM) Healthcare Conference would be held virtually in 2022, hotel prices in San Francisco plummeted from thousands of dollars per night to a few hundred for the same rooms. Some 24 hours later, Biotech Showcase – a premier partnering event for small biotech companies – also announced its […]

The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer, according to interim data from the dose-expansion portion of the phase 1 STRO-002-GM1 trial (NCT03748186).1 As of the interim data cutoff date of November 8, 2021, the ADC produced an objective response rate (ORR) of […]

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. In this interview, CEO Paul Wotton discusses the applications of Obsidian’s cytoDrive technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy. Please describe the story behind the company: What sparked the idea, and […]